← Leaderboards
Paul M Sondel
University Of Wisconsin Madison
$16,210,986
Attributed
$16,210,986
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$16,210,986 · 15
By mechanism
R01$7,642,739 · 3
R35$6,381,400 · 1
P01$1,581,507 · 2
M01$511,540 · 8
U54$93,800 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Mark R Albertini$1,770,800
Others in their field
Top investigators on “Monoclonal Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$276,346,332
- Lawrence Corey · Fred Hutchinson Cancer Center$271,417,082
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$257,261,947
- Peter B. Gilbert · Fred Hutchinson Cancer Center$190,281,881
- Barton F Haynes · Duke University$125,632,198
Research focus
Monoclonal AntibodiesTumorMelanomaClinical ResearchNeuroblastomaNeoplastic CellMalignant NeoplasmsImmuneCellsResponseAntibodiesChildRegimenPreventFutureIn VivoNatural Killer CellsClinical TrialsPre-ClinicalBaseImmune SystemMacrophageEffector CellCancer Therapy
Grant awards (55)
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses$296,214
P01 · FY2024 · CA · contact PI
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses$314,928
P01 · FY2023 · CA · contact PI
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses$316,027
P01 · FY2022 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$913,712
R35 · FY2021 · CA · contact PI
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses$327,645
P01 · FY2021 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$913,712
R35 · FY2020 · CA · contact PI
Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses$326,693
P01 · FY2020 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$886,301
R35 · FY2019 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$915,223
R35 · FY2018 · CA · contact PI
Discovery and development of pediatric cancer antigen targets recognized by adaptive immune response$93,800
U54 · FY2018 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$917,202
R35 · FY2017 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$917,625
R35 · FY2016 · CA · contact PI
Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome$917,625
R35 · FY2015 · CA · contact PI
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy$328,681
R01 · FY2014 · CA · contact PI
Clinical Development of HU14.18-IL2 Targeted Therapy$302,121
R01 · FY2014 · CA · contact PI
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy$318,902
R01 · FY2013 · CA · contact PI
Clinical Development of HU14.18-IL2 Targeted Therapy$292,778
R01 · FY2013 · CA · contact PI
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy$339,250
R01 · FY2012 · CA · contact PI
Clinical Development of HU14.18-IL2 Targeted Therapy$311,465
R01 · FY2012 · CA · contact PI
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages$261,901
R01 · FY2012 · CA · contact PI
Clinical Development of HU14.18-IL2 Targeted Therapy$311,465
R01 · FY2011 · CA · contact PI
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages$261,901
R01 · FY2011 · CA · contact PI
Clinical Development of HU14.18-IL2 Targeted Therapy$321,099
R01 · FY2010 · CA · contact PI
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages$270,001
R01 · FY2010 · CA · contact PI
Clinical Development of Hu14.18-IL2 Targeted Therapy$308,597
R01 · FY2009 · CA · contact PI
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages$270,001
R01 · FY2009 · CA · contact PI
Clinical Development of Hu14.18-IL2 Targeted Therapy$308,597
R01 · FY2008 · CA · contact PI
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages$270,001
R01 · FY2008 · CA · contact PI
Clinical Development of Hu14.18-IL2 Targeted Therapy$308,597
R01 · FY2007 · CA · contact PI
PHASE II TRIAL OF HU1418-IL2 (EMD 273063) IN SUBJECTS WITH ADVANCED MELANOMA$8,520
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF FENRETINIDE LXS ORAL POWDER IN PATIENTS WITH NEUROBLASTOMA$1,036
M01 · FY2007 · RR · contact PI
131I-MIBG WITH INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE$92
M01 · FY2007 · RR · contact PI
Clinical Development of Hu14.18-IL2 Targeted Therapy$317,814
R01 · FY2006 · CA · contact PI
PHASE II TRIAL OF HU1418-IL2 (EMD 273063) IN SUBJECTS WITH ADVANCED MELANOMA$32,891
M01 · FY2006 · RR · contact PI
131I-MIBG WITH INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE$714
M01 · FY2006 · RR · contact PI
T-Cell Independent Antitumor Mechanisms of CD40 Ligation$258,990
R01 · FY2005 · CA
CLINICAL DEVELOPMENT OF HU14.18 IL2 TARGETED THERAPY$316,495
R01 · FY2004 · CA
T-Cell Independent Antitumor Mechanisms of CD40 Ligation$258,990
R01 · FY2004 · CA
Phase I Trial of hu14.18-IL-2 in Neuroblastoma and Other GD2+ Tumors$16,177
M01 · FY2004 · RR
CLINICAL DEVELOPMENT OF HU14.18 IL2 TARGETED THERAPY$308,376
R01 · FY2003 · CA
T-Cell Independent Antitumor Mechanisms of CD40 Ligation$258,990
R01 · FY2003 · CA
CLINICAL DEVELOPMENT OF HU14.18 IL2 TARGETED THERAPY$300,493
R01 · FY2002 · CA
T-Cell Independent Antitumor Mechanisms of CD40 Ligation$258,990
R01 · FY2002 · CA
MAINTENANCE TREATMENT OF THERAPY REFRACTORY ALL W/ B43 PAP IMMUNOTOXI$106,600
M01 · FY2002 · RR
PHASE I STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN$106,600
M01 · FY2002 · RR
CLINICAL DEVELOPMENT OF HU14.18 IL2 TARGETED THERAPY$292,837
R01 · FY2001 · CA
PHASE I STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN$106,600
M01 · FY2001 · RR
MAINTENANCE TREATMENT OF THERAPY REFRACTORY ALL W/ B43 PAP IMMUNOTOXI$106,600
M01 · FY2001 · RR
MAINTENANCE TREATMENT OF THERAPY REFRACTORY ALL W/ B43 PAP IMMUNOTOXI$12,855
M01 · FY2001 · RR
PHASE I STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN$12,855
M01 · FY2001 · RR
CLINICAL DEVELOPMENT OF HU14.18 IL2 TARGETED THERAPY$285,407
R01 · FY2000 · CA
MAINTENANCE TREATMENT OF THERAPY REFRACTORY ALL W/ B43 PAP IMMUNOTOXI$0
M01 · FY2000 · RR
PHASE I STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN$0
M01 · FY2000 · RR
PHASE I STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN$0
M01 · FY2000 · RR
MAINTENANCE TREATMENT OF THERAPY REFRACTORY ALL W/ B43 PAP IMMUNOTOXI$0
M01 · FY2000 · RR